AMYLOID LIGHT-CHAIN AMYLOIDOSIS

Clinical trials for AMYLOID LIGHT-CHAIN AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new AMYLOID LIGHT-CHAIN AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for AMYLOID LIGHT-CHAIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

New drug combo aims to wipe out rare blood disease

Disease control Recruiting now

This study tests whether a combination of two drugs, teclistamab and daratumumab, can safely and effectively treat AL amyloidosis, a rare disease where abnormal proteins damage organs. The treatment lasts 6 months and involves 25 adults who have not received prior therapy. The ma…

Matched conditions: AMYLOID LIGHT-CHAIN AMYLOIDOSIS

Phase: PHASE2 • Sponsor: Suzanne Lentzsch, MD • Aim: Disease control

Last updated Apr 26, 2026 19:38 UTC

AMYLOID LIGHT-CHAIN AMYLOIDOSIS

Get alerted when new AMYLOID LIGHT-CHAIN AMYLOIDOSIS trials appear

New drug combo aims to wipe out rare blood disease